Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/22/22
End: 10/31/24
Due: 10/31/25
Phase: N/A
Priority: Normal
Start: 06/01/24
End: 09/01/28
Due: 09/01/29
Phase: N/A
Priority: Normal
Start: 07/05/24
End: 06/05/25
Due: 06/05/26
Phase: N/A
Priority: Normal
Start: 05/01/24
End: 05/01/29
Due: 05/01/30
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| The Influence of Splenic Artery Characteristics in Gastric Cancer Surgery | NCT06680362 | xiaohua li | user2@example.com | None | 2022-05-22 | 2024-10-31 | 2025-10-31 | - | - | 2025-07-14 |
| Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: | NCT06411171 | xiaohua li | user2@example.com | None | 2024-06-01 | 2028-09-01 | 2029-09-01 | - | - | 2025-07-14 |
| To Explore the Efficacy of Sintilimab Combined with Bevacizumab in Rectal Cancer | NCT06808412 | xiaohua li | user2@example.com | None | 2024-07-05 | 2025-06-05 | 2026-06-05 | - | - | 2025-07-14 |
| A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab | NCT06681298 | xiaohua li | user2@example.com | None | 2024-05-01 | 2029-05-01 | 2030-05-01 | - | - | 2025-07-14 |